Fig. 1: qHTCS identifies MITF inhibitor ML329 that overcomes palbociclib resistance.
From: O-GlcNAcylation of MITF regulates its activity and CDK4/6 inhibitor resistance in breast cancer
a Schematic of qHTCS to identify ML329 that can overcome palbociclib resistance. b Surface plots (top) and synergy matrix (bottom) to exhibit the synergy between palbociclib and ML329 in MCF-7 PR and T-47D PR cells (n = 3 independent experiments). c Edu staining to measure the S phase population in MCF-7 PR cells treated as indicated. The scale bar represents 20 μm. (n = 3 independent experiments). d, e Representative images of colony formation (d) and quantification results (e) in MCF-7 PR and T-47D PR cells with indicated treatments (n = 3 independent experiments). f, g Representative images (f) and growth curves (g) of MCF-7 PR xenograft tumors treated with saline, palbociclib (25 mg/kg), ML329(5 mg/kg), or a combination of both for 3 weeks. n = 6 mice/group. **p ≤ 0.01. All error bars are expressed as mean ± SEM. Two-tailed Student’s t tests were employed for statistical evaluation. Source data are provided as a Source Data file.
